APELIN OF BLOOD IN PATIENTS WITH ESSENTIAL HYPERTENSION AND TYPE 2 DIABETES AND WITHOUT IT IN THE DINAMICS OF COMBINED THERAPY
In the course of the study, there were examined 40 patients with hypertension, including 19 patients with associated type 2 diabetes before and after 12 weeks of treatment with olmesartan and lercanidipine during the therapy with atorvastatin. The patients with type 2 diabetes were additionally treated with metformin. The control group consisted of 10 practically healthy people. We found that in hypertensive patients with type 2 diabetes, the blood levels of apelin were lower than those in the control group. Among hypertensive patients without type 2 diabetes, the blood levels of apelin depend on diastolic blood pressure, lipid parameters, left atrium size, aortic diameter. In patients with combination of hypertension and type 2 diabetes, apelin correlated with duration of hypertension, diastolic blood pressure, atherogenic factor and left atrium size. In hypertensive patients with type 2 diabetes, a significant increase in blood levels of apelin after treatment was found in comparison with its basal levels. These data confirm the participation of endogenous peptide apelin in the processes of blood pressure regulation, atherogenesis and pathological cardiac remodeling in hypertensive patients with type 2 diabetes and without it.
Koval SN, Yushko KA, Starchenko TG. Apelin of blood in patients with essential hypertension and type 2 diabetes and without it in the dinamics of combined therapy. Research Result. Medicine and Pharmacy Series. 2014;1(2):4-11 (In Russian). DOI: 10.18413 / 2313-8955-2014-1-2-4-11
While nobody left any comments to this publication.
You can be first.
1. Pisarenko O.P., Serebryakova L.I., Pelogeykina Yu.A. Participation of NO-dependent Mechanisms of Apelin Action in the Protection of the Myocardium from Ischemia and Reperfusion Injury // Cardiology. 2012. № 2. pp. 52-58.
2. Barnes G., Japp A.G., Newby D.E. Translational promise of the apelin-APJ system // Heart. 2010. Vol. 96(13). pp.1011-1016.
3. Baysal S.S. et al. Сhange in apelin level in response to treatment and relation with diastolic function in patients with newly diagnosed hypertension / Int.J.of Card. 163S1. 2013. P.15.
4. Cavallo M.G., Sentinelli F., Barchetta I. et al. Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus // PLoS One. 2012. Vol.7(12). e51236.
5. Dray C., Knauf C., Daviaud D. et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice // Cell. Metab. 2008. Vol. 8. pp. 437 - 445.
6. Erdem G., Dogru T., Tasci I. et al. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus // Exp Clin Endocrinol Diabetes. 2008. Vol.116(5). pp.289-92.
7. Falcone C., Buzzi M.P., Dangelo A. et al. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation // Int. J. Immunopathol. Pharmacol. 2010. Vol. 23. pp. 917-925.
8. Isabelle Castan-laurell, Cédric Dray, Claude Knauf. Apelin, a promising target for type 2 diabetes treatment? // Trends in Endocrinology & Metabolism. – 2012. Vol. 23(5). pp. 234-241.
9. Japp A.G., Cruden N.L., Barnes G. et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure // Circulation. 2010. Vol. 121(16). pp. 1818-1827.
10. Kallergis E.M., Manios E.G., Kanoupakis E.M. et al. Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial fibrillation // Am J Cardiol. – 2010. Vol. 105(1). pp. 90-94.
11. Koguchi W., Kobayashi N., Takeshima H. et al. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure // Circ. J. 2012. Vol. 76(1). pp. 137–144
12. Lv D., Li H., Chen L. Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis // Acta Biochim Biophys Sin (Shanghai). 2013. Vol. 45(7). pp. 527-533.
13. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J Hypertens. 2013. Vol.31(7). pp. 1281-1357.
14. Papadopoulos D.P., Mourouzis I., Faselis C. et al. Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels // J Clin Hypertens (Greenwich). 2013. Vol.15(5). pp. 333-336.
15. Pitkin S.L., Maguire J.J., Bonner T.I. et al. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function // Pharmacol Rev. 2010. Vol. 62(3). pp. 331-342.
16. Seyyed M. R. Kazemi-Bajestani, Vaibhav B. Patel, Wang Wang et al. Targeting the ACE2 and apelin pathways are novel therapies for heart failure: opportunities and challenges // Cardiology Research and Practice. 2012. Vol. 2012 (2012), Article ID 823193, 11 pages.
17. Shiming Xu, Philip S. Tsao, Patrick Yue. Apelin and insulin resistance: another arrow for the quiver? // J Diabetes. 2011. Vol. 3(3). pp. 225-231.
18. Soriguer F., Garrido-Sanchez L., Garcia-Serrano S. et al. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus // Obes Surg. 2009. Vol. 19(11). pp. 1574-1580.
19. Tasci I., Dogru T., Nacharci I. et al. Plasma apelin is lower in patients with elevated LDL-cholesterol // Exp. Clin. Endocrinol. Diabetes. 2007. Vol. 115 (7). pp. 428-432.
20. Tycinska A.M., Lisowska A., Musial W.J. et al. Apelin in acute myocardial infarction and heart failure induced by ischemia // Clin. Chim. Acta. 2012. Vol. 413(3-4). pp. 406-410.
21. Zheng Tian-Peng, Guo Chang-Hui, Zhou Ting-Ting et al. The relationship between plasma apelin-12 level and hypertension, insulin resistance of type 2 diabetes mellitus patients // Chinese Journal of Gerontology. 2010. Issue 4. pp. 435-437.